» Articles » PMID: 32881860

Risk Factors Associated with Mortality in Hospitalized Patients with SARS-CoV-2 Infection. A Prospective, Longitudinal, Unicenter Study in Reus, Spain

Overview
Journal PLoS One
Date 2020 Sep 4
PMID 32881860
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Spain is one of the countries that has suffered the most from the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the strain that causes coronavirus disease 2019 (COVID-19). However, there is a lack of information on the characteristics of this disease in the Spanish population. The objective of this study has been to characterize our patients from an epidemiological point of view and to identify the risk factors associated with mortality in our geographical area. We performed a prospective, longitudinal study on 188 hospitalized cases of SARS-Cov-2 infection in Hospital Universitari de Sant Joan, in Reus, Spain, admitted between 15th March 2020 and 30th April 2020. We recorded demographic data, signs and symptoms and comorbidities. We also calculated the Charlson and McCabe indices. A total of 43 deaths occurred during the study period. Deceased patients were older than the survivors (77.7 ± 13.1 vs. 62.8 ± 18.4 years; p < 0.001). Logistic regression analyses showed that fever, pneumonia, acute respiratory distress syndrome, diabetes mellitus and cancer were the variables that showed independent and statistically significant associations with mortality. The Charlson index was more efficient than the McCabe index in discriminating between deceased and survivors. This is one of the first studies to describe the factors associated with mortality in patients infected with SARS-CoV-2 in Spain, and one of the few in the Mediterranean area. We identified the main factors independently associated with mortality in our population. Further studies are needed to complete and confirm our findings.

Citing Articles

Differential analysis of lipoprotein and glycoprotein profiles in bacterial infections and COVID-19 using proton nuclear magnetic resonance and machine learning.

Iftimie S, Amigo N, Martinez-Micaelo N, Lopez-Azcona A, Martinez-Navidad C, Castane H Heliyon. 2024; 10(17):e37115.

PMID: 39286163 PMC: 11402779. DOI: 10.1016/j.heliyon.2024.e37115.


A Theoretical Death Map of Patients with COVID-19: A Single Center Experience.

Salimi R, Mohammadpour A, Bouraghi H, Pashangpoor K Tanaffos. 2024; 22(4):357-365.

PMID: 39176148 PMC: 11338515.


Retrospective Analysis of Infection Rates and Outcomes in Hospitalized Patients during the COVID-19 Pandemic: A Unicenter Study in Reus, Spain.

Iftimie S, Lopez-Azcona A, Corchero-Valverde M, Peralta-Vazquez A, Lopez-Cordon L, Garcia-Cervera C J Clin Med. 2024; 13(10).

PMID: 38792341 PMC: 11122305. DOI: 10.3390/jcm13102799.


Association between biochemical and hematologic factors with COVID-19 using data mining methods.

Mansoori A, Hosseini N, Ghazizadeh H, Aghasizadeh M, Drroudi S, Sahranavard T BMC Infect Dis. 2023; 23(1):897.

PMID: 38129798 PMC: 10734144. DOI: 10.1186/s12879-023-08676-0.


Combinatorial analysis of ACE and ACE2 polymorphisms reveals protection against COVID-19 worsening: A genetic association study in Brazilian patients.

Sousa R, Nascimento L, Costa L, Leite V, Borges C, Deus J PLoS One. 2023; 18(11):e0288178.

PMID: 38032879 PMC: 10688632. DOI: 10.1371/journal.pone.0288178.


References
1.
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R . Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7):894-901. PMC: 7270947. DOI: 10.1016/j.annonc.2020.03.296. View

2.
Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D . Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020; 47(5):1275-1280. PMC: 7080117. DOI: 10.1007/s00259-020-04735-9. View

3.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

4.
Anderson R, Heesterbeek H, Klinkenberg D, Hollingsworth T . How will country-based mitigation measures influence the course of the COVID-19 epidemic?. Lancet. 2020; 395(10228):931-934. PMC: 7158572. DOI: 10.1016/S0140-6736(20)30567-5. View

5.
Lim W, van der Eerden M, Laing R, Boersma W, Karalus N, Town G . Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. PMC: 1746657. DOI: 10.1136/thorax.58.5.377. View